Galectin Therapeutics (FRA:PHPN) YoY EBITDA Growth : 17.68% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Galectin Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Galectin Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 17.68%.

Galectin Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was €-0.14.

Galectin Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Galectin Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics YoY EBITDA Growth Chart

Galectin Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

25.08

-48.02

-35.12

-31.94

2.67

Galectin Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial															-59.22	-16.89	12.08	-6.38	17.68

Galectin Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Galectin Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-0.583	-	-0.599)	/	\| -0.599 \|
=	2.67 %

Galectin Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-0.135	-	-0.164)	/	\| -0.164 \|
=	17.68 %

Galectin Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Galectin Therapeutics (FRA:PHPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (FRA:PHPN) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

GALT:USA

Address

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071

Website

https://www.galectintherapeutics.com

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Galectin Therapeutics (FRA:PHPN) Headlines

No Headlines